Forum udruge "Zajedno do zdravlja" Dubrovnik https://zajedno-do-zdravlja.hr:443/forum/ |
|
Pojmovi o lijekovima za JIA https://zajedno-do-zdravlja.hr:443/forum/viewtopic.php?f=9&t=142 |
Stranica: 1/1. |
Autor: | kate [ 29-01-2009 16:03 ] |
Naslov: | Pojmovi o lijekovima za JIA |
1. linija lijekova (NSAID-NESTEROIDNI PROTUUPALNI LIJEKOVI) - "Movalis" genericki Meloxicam http://www.belupo.hr/Default.aspx?sid=2 ... onOTC=true - "Dalsy" generički Ibuprofen http://www.belupo.hr/Default.aspx?sid=4 ... table.ascx - "Indometacin" genericki Indometacin http://www.belupo.cz/Default.aspx?sid=1 ... onOTC=true - "Nalgesin" generički Naproxen http://www.tegobe.com/vademecumi/krka/nalgesin.html 2. linija lijekova (DMARD-LIJEKOVI KOJI MODIFICIRAJU TIJEK BOLESTI ) daju se dodatno na prvu liniju lijekova - generički Metotrexate skraceno MTX daje se u tabletama ili potkozno http://www.plivazdravlje.hr/pda/?sectio ... u2=&id=170 http://www.jrheum.com/abstracts/editorials/990827.html - "Arava" genericki Leflunomide http://www.rheumatology.org/public/fact ... nomide.pdf http://www.arava-lawyer.com/arava_links.html http://www.fda.gov/cder/foi/label/2005/ ... 015lbl.pdf http://www.arava.com/hcp/default.aspx -"Imuran" generički Azathioprine http://en.wikipedia.org/wiki/Azathioprine http://www.gsk.com.au/resources.ashx/pr ... ablets.pdf http://www.gsk.com.au/resources.ashx/pr ... ection.pdf 3. linija lijekova (DMARD Anti-TNF.. BIOLOŠKI LIJEKOVI) daju se dodatno na prvu i drugu liniju lijekova - "REMICADE" genericki Infliximab kimericno misje-humano protutijelo, daje se infuzijom svaka 2 mjeseca http://www.remicade.com/remicade/global/index.html - "Humira" genericki Adalimumab humano monoklonsko protutijelo, daje se potkozno svaka 2 tjedna http://www.humira.com/ http://www.pcpoh.bham.ac.uk/publichealt ... imumab.pdf - "Enbrel" genericki Etanercept potpuni humani solubilni TNF receptor, daje se potkozno jednom ili dva puta tjedno http://www.enbrel.com/ http://www.keele.ac.uk/schools/pharm/MT ... CEPTRA.PDF - ORENCIA(R) (abatacept) http://www.prnewswire.com/cgi-bin/stori ... 045&EDATE= Glukokortikoidi Glukokortikoidi su lijekovi iz grupe steroidnih hormona sa snažnim protuupalnim i imunosupresivnim djelovanjem. Koriste se kao dopuna temeljnim lijekovima na početku liječenja. Primjenjuju se u težim formama bolesti sa zahvaćanjem unutarnjih organa i kao trajna terapija. Mogu se primijeniti u formi injekcija u zglobove |
Autor: | kate [ 30-01-2009 21:09 ] |
Naslov: | |
Pitanje o ARAVI http://www.cybermed.hr/index.php/pbl/po ... ijom/arava |
Autor: | kate [ 30-01-2009 23:40 ] |
Naslov: | |
MTX ili ARAVA što je bolje? http://www.webmd.com/rheumatoid-arthrit ... uvenile-ra https://content.nejm.org/cgi/reprint/35 ... pdf?ck=nck |
Autor: | kate [ 03-02-2009 13:51 ] |
Naslov: | |
Folna kiselina Prilikom ljecenja MTX-om koji je antagonist folne kiseline, mora se nadomjestiti folna kiselina suplementima tipa Folacin koji smanjuju nuspojeve MTX-a, te nadoknadjuju folnu kiselinu. o folnoj kiselini opcenito http://www.coolinarika.com/clanak/folna-kiselina http://www.ncbi.nlm.nih.gov/books/bv.fc ... er.a682591 Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis http://www.clinexprheumatol.org/pdf/vol ... avelli.pdf Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid http://www.ncbi.nlm.nih.gov/pubmed/1079 ... rom=pubmed http://www.ncbi.nlm.nih.gov/pubmed/9517 ... rom=pubmed Leucovorin http://www.ncbi.nlm.nih.gov/books/bv.fc ... er.a682336 |
Autor: | kate [ 05-02-2009 21:13 ] |
Naslov: | |
Is there a consensus for the dosage of folic acid to be given as local rheumatalogists vary from 5mg daily to 10mg weekly? Is there any indication for taking the weekly amount 1 day prior to taking methotrexate? http://www.attract.wales.nhs.uk/questio ... on_id=2288 |
Autor: | kate [ 05-02-2009 23:34 ] |
Naslov: | |
Kortikosteroidi Corticosteroids for juvenile rheumatoid arthritis http://www.questdiagnostics.com/kbase/t ... detail.htm |
Autor: | kate [ 10-02-2009 14:51 ] |
Naslov: | |
Humira- Adalimumab in the therapy of uveitis in childhood. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M. Department of Ophthalmology, University of Tuebingen, Tuebingen, Germany. PURPOSE: Chronic anterior uveitis in children often takes a serious course. Despite various immunosuppressive drugs some children do not respond sufficiently and there is a high risk of them becoming seriously disabled. Anti-TNF alpha therapy has been shown by our group and others to be mostly ineffective (Etanercept) or partly effective (Infliximab) with the risk of anaphylactic reactions. Here we report on 18 young patients treated with Adalimumab (Humira), a complete humanised anti-TNF alpha antibody. METHODS: We retrospectively analysed 18 patients, who were treated with Adalimumab (20-40 mg, every 2 weeks, when ineffective every week); 17 had juvenile idiopathic arthritis, one was without detectable underlying disease. The age at onset of arthritis varied from 0.5-15 years and for uveitis from 2-19 years. Patients were included when the previous anti-inflammatory therapy had been ineffective. It consisted of systemic steroids (n = 18), Cyclosporin A (n = 18), Methotrexate (n = 18), Azathioprine (n = 12), Mycophenolate mofetil (n = 4), Cyclophosphamide (n = 2), Leflunomide (n = 3), Etanercept (n = and Infliximab (n = 5). The grading for uveitis was: (a) effective: no relapse or more than two relapses less than before treatment, (b) mild: one relapse less than before treatment, (c) no response: no change in relapse rate and (d) worsening: more relapses under treatment than before. The grading for arthritis (depending on the clinical findings), using three out of six parameters of the ACR PED Criteria, was: effective, mild, no response, worsening. RESULTS: For arthritis (n = 16) the response to Adalimumab was effective in 10 of 16 patients, mild in three patients, three did not respond. For uveitis (n = 18) Adalimumab was effective in 16, mild in one child, and one patient did not show any effect. After a very good response initially a shorter application time had to be used to maintain the good anti-inflammatory effect in one child. Additional immunosuppressive treatment was used in seven of the effectively treated children. Due to elevation of liver enzymes in one patient, who also took MTX, Adalimumab had to be discontinued. No anaphylactic reactions or increased frequency of infections since start of Adalimumab treatment was reported. CONCLUSIONS: For our group of children with long lasting disease our results show that Adalimumab was effective or mildly effective against the arthritis in 81%, but in uveitis in 88%. While these results regarding arthritis are comparable with other TNF-alpha blocking drugs (Etanercept), Adalimumab seems to be much more effective against uveitis than Etanercept. Anaphylactic reactions, found in a previous study from our group after Infliximab treatment, were not seen with Adalimumab. The necessary dosage and the treatment period, which probably have to be defined individually for each patient, remain unclear http://www.ncbi.nlm.nih.gov/pubmed/17035274 http://www.cornellpediatrics.org/bm~doc ... veitis.pdf Adalimumab and severe uveitis in juvenile idiopathic arthritis (JIA)therapy http://www.ped-rheum.com/content/pdf/15 ... S1-P76.pdf |
Autor: | dragica1 [ 27-11-2012 20:39 ] |
Naslov: | Re: Pojmovi o lijekovima za JIA |
Vjrovatno ste već pročitali ali nema veze,ima gore više sve o Aravi i ostalim lijekovima http://www.almp.hr/upl/lijekovi/PIL/UP- ... 02-174.pdf |
Stranica: 1/1. | Vremenska zona: UTC + 01:00 |
© 2000, 2002, 2005, 2007 phpBB Group • http://www.phpbb.com |